BioLight Reports First Quarter 2015 Financial Results

BioLight today reported operational and financial results for the first quarter ended March 31, 2015.

Operational Highlights:

  • Reported clinical study findings that identified positive statistical correlations between the TeaRx™ test’s diagnostic parameters and widely used benchmark tests for dry eye syndrome.
  • Reported that a blinded, multi-center clinical study of the CellDetect® non-invasive test for detecting bladder cancer in urine successfully achieved its primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.
  • Completed an investment in OphRx, a newly-formed ophthalmic company that has in-licensed a drug-delivery platform that has the potential to enable more efficient and safer delivery of eye drops.
  • Announced first IOPtiMate™ System sales in new territories as well as, subsequent to the end of Q1, the first sale of the IOPtiMate™ system procedures.
  • Subsequent to the end of Q1, signed a strategic partnership with Rock-One International Holdings Ltd., designed to help BioLight maximize its presence within China, the second largest healthcare market in the world after the U.S.

Link to complete article

Link to Q1-2015 financial results

Link to Newsroom

Comments are closed